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ABSTRACT
We studied the presence of mutations in the whole katG gene and specific regions of the oxyR-ahpC and mabA-
inhA regulatory region in 61 Mycobacterium tuberculosis isoniazid-resistant isolates. An 81-bp region of the
rpoB gene was also sequenced in 17 rifampin-resistant strains. Alterations in the katG gene were detected in
55% of the isolates. Mutation in codon 315 was the most prevalent (32%). Strains showed a high level of re-
sistance, and most maintained a substantial catalase-peroxidase activity. Three strains with an isoniazid MIC
of 32 g/ml lacked catalase-peroxidase activity. Two of them had deletions in the catalytic domain of the
KatG protein. One strain with deletion and three strains with mutations in the C-terminal domain showed
low-level resistance and conserved the catalase-peroxidase activity. Mutations in the mabA-inhA regulatory
region were identified in 32% of the isolates. All had low-level resistance, and the vast majority conserved
catalase-peroxidase activity. Seventeen percent of the isoniazid-resistant isolates had no detectable alterations
at the studied loci. Resistance to rifampin was associated with mutations in the 81-bp of the rpoB gene in all
cases. IS6110 analysis indicated that recent transmission contributed substantially to the emergence of isoni-
azid-resistant tuberculosis in Barcelona through short transmission chains. A rapid genotypic assay, includ-
ing the 315-katG codon and the 15 nucleotide of the mabA-inhA regulatory region, may cover 62% of iso-
niazid-resistant strains in Barcelona. In contrast, the targeting of the 81-bp region of rpoB would detect all
our rifampin-resistant isolates.
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INTRODUCTION
TUBERCULOSIS (TB) is presently the second leading cause ofadult mortality due to infectious diseases and is responsi-
ble for approximately 2 million deaths a year worldwide. WHO
estimates that one-third of the world’s population is infected
with Mycobacterium tuberculosis.56 Multidrug-resistant tuber-
culosis (MDR-TB) is an emerging public health problem in
many regions of the world, particularly in developing nations.55
Accurate and rapid diagnosis is essential in the management of
drug and MDR-TB, not only to optimize treatment but also to
prevent transmission. The retrieval of antibiograms for M. tu-
berculosis is severely delayed when drug susceptibility testing
is culture based. Understanding the genetic events leading to
drug resistance in clinical M. tuberculosis isolates, as well as
their prevalence in different geographic areas, makes it possi-
ble to develop rapid genetic assays for their detection.10,32,48
Mutations in an 81-bp “core region” of rpoB gene have been
found in approximately 95% of rifampin (RIF)–resistant
strains.7,47 In contrast, resistance to isoniazid (INH) is associ-
ated with a variety of mutations affecting one or more genes.
Isoniazid is a pro-drug that requires activation by the catalase-
peroxidase KatG. The resulting active principle, still unknown,
inhibits the activity of the InhA enzyme that belongs to a type
II fatty acid elongation system together with KasA/KasB and
MabA. Several studies have revealed that mutations in the katG
gene are responsible for 60–70% of INH-resistant strains,31 with
the majority of mutations occurring at codon 315. Isolates that
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carry other less frequently occurring mutations in katG have
been described,24,29,34 but few studies have sequenced the com-
plete katG gene. Mutations in the mabA-inhA regulatory region
that exhibit both low-level INH resistance and ethionamide re-
sistance have been found in clinical isolates.2,46 It has been pro-
posed that over-expression of the protein may explain isoniazid
resistance. Less commonly, strains with mutations in the struc-
tural gene inhA have been described.30 The role of mabA and
kasA mutations in isoniazid resistance remains unclear. Muta-
tions in the oxyR-ahpC region, a gene that encodes an alkyl hy-
droperoxidase reductase (AhpC), do not appear to play a direct
role in INH resistance, although they may be important in main-
taining peroxide homeostasis of the organism when KatG ac-
tivity is low or absent.14
A priority of TB control programs is to prevent the trans-
mission of resistant strains by early detection and appropriate
treatment. Only cases of drug resistance among new cases are
assumed to be due to transmission of drug-resistant strains.31
Many outbreaks of drug-resistant strains in community settings
have been described using IS6110–RFLP analysis, the stan-
dardized and most widely applied molecular typing method for
M. tuberculosis.8
Our aim was to prospectively analyze the prevalence of mo-
lecular genetic mechanisms for M. tuberculosis INH and RIF
resistance in the urban area of Barcelona. We also compared
the genotypic analysis with phenotypic properties such as cata-
lase-peroxidase activity or minimum inhibitory concentration
(MIC) of INH. Finally, we assessed the community transmis-
sion of drug-resistant tuberculosis. 
MATERIALS AND METHODS
Study setting, patients, and isolates
In a previously published project,23 Mycobacterium tuber-
culosis isolates were collected from 1,749 consecutive tuber-
culosis patients attending the six tertiary hospitals of the
Barcelona area over a 2-year period (from October 1995 to Sep-
tember 1997). Most patients (1,535; 87.8%) had no history of
previous treatment. A rate of 5.7% drug resistance among new
cases and 20.5% drug resistance among previously treated pa-
tients was observed. The number of INH- and RIF-resistant
strains was 58 (3.8%) and 15 (1%), respectively. The same fig-
ures for INH and RIF resistance among previously treated pa-
tients were 37 (17.3%) and 21 (9.8%), respectively.23 Isoniazid
resistance among new cases was associated with foreign peo-
ple. Drug resistance among previously treated patients was as-
sociated with people over 60 years old and women.23 A sam-
ple of 61 INH-resistant strains and 17 RIF-resistant strains was
available for study.
Laboratory procedures
Phenotypic drug susceptibility testing was carried out using
the BACTEC 460 radiometric method (Becton Dickinson, Tow-
son, MD), which contained critical concentrations of 0.1 g/ml
of isoniazid and 2 g/ml of rifampin. In strains resistant to INH
and RIF, MICs were obtained in Middlebrook 7H10 medium
incubated for 3 weeks. Six dilutions of INH and RIF were pre-
pared to give final concentrations of 0.125, 0.25, 0.5, 1, 2, 4,
8, 16, and 32 g/ml in the plate. The catalase and peroxidase
activities were semiquantitatively determined with the Bogen
reactive following a standard protocol.5
Epidemiological characterization
In order to rule out outbreaks that could influence the rela-
tive importance of drug resistance mechanisms, isolates were
typed by a standard IS6110-based restriction fragment length
polymorphism (RFLP) method.51 Banding patterns were ana-
lyzed using BioImage whole-band analysis software (Genomic
Solutions, Inc., Ann Arbor, MI). Banding patterns were com-
pared by the Dice coefficient to calculate similarities. The un-
weighted pair group method using arithmetic averages was used
for clustering. Patients were grouped in the same cluster if their
isolates were identical with respect to the number and size of
hybridizing bands when six or more bands are present.22
Detection of mutation
The isolates were cultured on Lowenstein-Jensen slants.
Colonies were scraped, resuspended in 500 l of TE (10 mM
Tris, 1 mM EDTA [pH 8]), and killed by freezing at 70°C
followed by heating at 80°C for 20 min. The DNA was ex-
tracted using a previously described protocol.52 The entire katG
gene (six fragments; 2405 bp), specific regions of the oxyR-
ahpC located upstream of the gene (105 bp) and the mabA-inhA
regulatory region (248 bp) related to isoniazid resistance, and
the region of the rpoB gene (165 bp) involved in rifampin re-
sistance were PCR amplified. The primers used for rpoB gene
were designed with the program Primer Express (Applied
Biosystems) and the primers for other target regions were de-
rived from published sequences44,46 (Table 1). DNA sequenc-
ing was performed with the fmol DNA Cycle Sequencing Sys-
tem (Promega Corporation, Madison, WI) with ALF Express II
(Amersham Pharmacia Biotech).
RESULTS
Genotypic analysis of M. tuberculosis isolates
Of the 61 INH-resistant strains, 46 (75%) had a unique
IS6110 RFLP pattern and 15 (25%) matched at least one other
isolate belonging to one of seven clusters of drug-resistant iso-
lates. All clusters contained RFLP patterns (A–G) with more
than six bands (Table 2). Twelve out of 15 clustered patients
were in six clusters of two, and the others were in a cluster of
three.
Conventional contact tracing showed that the two patients
with isolates of pattern A had been living together. All other
patients, whose isolates had shared patterns, had no discernible
connection with each other.
Isolates belonging to one of seven clusters had different re-
sistance patterns. Thus, pattern B was seen in two isolates, one
resistant to INH (katG and inhA wild-type) and the other re-
sistant to INH and RIF (katG and inhA wild-type and rpoB
S531L). A representative of each cluster was chosen for the epi-
demiological analysis of resistance mechanisms. In the case of
cluster with several resistance phenotypes, the most resistant
strain was selected.
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Analysis of the rpoB gene responsible for the RIF
resistance phenotype
Mutations in the core region of rpoB gene were detected for
all 15 RIF-resistant strains. Eight different rpoB mutations were
identified involving codons 512, 516, 526, and 531. The most
common mutation, which changes serine to leucine (position
531), was detected in seven of the 15 RIF-resistant isolates
(Table 3).
Analysis of katG, inhA, and oxyR-ahpC genes
involved in the isoniazid resistance phenotype
As shown in Table 4, 29 of 53 INH-resistant strains (55%) had
katG alterations consisting of small deletions (3–15 nucleotides;
n  3) or nucleotide substitutions (n  26), resulting in either
amino acid replacement (n  25) or stop mutation (n  1). All
but two strains had a single alteration in the katG gene. The ge-
netic alterations were detected all along the gene: codons 94, 152,
172, 189, 204, 234, 315, 463, 560, 592, 640, 678, and 728. How-
ever, the most frequent mutation occurred at codon 315 (17 of 53;
32%), where the most common substitution was Ser  Thr (15
of 53; 28%). The second most frequently affected codon was the
463 with an Arg  Leu substitution (3 of 53; 6%).
mabA-inhA regulatory region analysis showed a nucleotide
substitution for 17 of the 53 INH-resistant strains (32%) with
the following changes: C  T substitution involving nucleotide
at the position 15 upstream of the mabA initiation codon (–15;
14 of 53; 26%); T  C involving nucleotide –8 (two of 53;
4%) and G  T involving nucleotide –17 (one of 53; 2%).
In the intergenic region oxyR-ahpC, 7 (13.2%) of those 53
INH-resistant strains had simple nucleotide substitutions (posi-
tions 6, 12, 39), deletions (position –39) or insertions (one
or two nucleotides; positions (–38/–39 and –45/–46; designated
relative to ahpC mRNA start site).
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TABLE 1. PRIMERS USED FOR AMPLIFICATION OF DNA SEGMENTS FROM RPOB, KATG,
MABA-INHA, AND OXYR-AHPC
Drug Gene Length of amplicon Sequence 5–3
Rifampin rpoB 165 5-accgcagacgttgatcaacat-3
5-ggcacgctcacgtgacag-3
Isoniazid katG 337 5-gtgcccgagcaacacccacc-3
5-taggtgccggcagcgtgcca-3
422 5-tggcacgctgccggcaccta-3
5-aatgtcgaccgccgcggcca-3
418 5-tggccgcggcggtcgacatt-3
5-ggtcagtggccagcatcgtc-3
406 5-ccgacgatgctggccactga-3
5-tcggggtcgttgacctccca-3
408 5-tgggaggtcaacgaccccga-3
5-ccagcgctaagcgcttgtag-3
414 5-ctacaagcgcttaccgctgg-3
5-caaatcgcgccgggcaaaca-3
mabA-inhA 248 5-cctcgctgcccagaaaggga-3
5-atcccccggtttcctccggt-3
oxyR-ahpC 105 5-gcttgatgtccgagagcatcg-3
5-ggtcgcgtaggcagtgcccc-3-
TABLE 2. GENOTYPIC DRUG RESISTANCE ANALYSIS OF 15 CLUSTERED INH-RESISTANT ISOLATES
RFLP pattern No. of
(no. of bands) isolates MIC (g/ml) katG mutation MIC, g/ml rpoB mutation
A (11) 2 8 S315Ta 0.06 —
B (13) 1 0.25 —c 0.06 —
1 0.25 — 32 S531La
C (13) 2 8 S315T 0.06 —
D (14)b 3 0.25 — 0.06 —
E (10) 2 8 S315T 32 S531L
F (13) 2 8 S315T 4 A516V
G (11) 2 8 S315T 0.06 —
aCodon number affected and amino acid substitution.
b
-15T nucleotide substitution of the mabA-inhA regulatory region.
c
—, Wild-type. All strains, including in the clusters, displayed the oxyR-ahpC region wild type.
INH RIF
INH MIC and catalase-peroxidase activity correlation
with genotype
MICs of isoniazid were 1 g/ml in 25 strains (47%), 2–16
g/ml in 18 (34%), and 32 g/ml in three (6%). MICs of the
17 strains with mutation in the regulatory region of inhA were
0.25–2 g/ml, 71% of them having a MIC of 0.25–0.5 g/ml.
MICs of the strains with mutation at codon 315 of katG gene
was 4–16 g/ml. Two of the three strains with MIC of 32
g/ml presented a deletion in the katG gene, and all strains
lacked catalase and peroxidase activity. The presence of cata-
lase activity was detected in 71% of the strains with mutation
at codon 315 of katG, and the peroxidase was detected in 35%
of these strains. The MICs of the strains with mutations in the
katG gene, but not in codon 315, was 0.125–2 g/ml. Catalase
activity was detected in 71% of these strains, whereas peroxi-
dase activity was detected in 42.8%. Ninety percent of the
strains with MIC of 1 g/ml conserved the catalase and per-
oxidase activities.
DISCUSSION
In this study, we report the presence of mutations in the core
region of rpoB gene in all the M. tuberculosis strains that ex-
hibited RIF resistance. The most frequent mutation (41%) oc-
curred at codon position 531. Although frequencies of particu-
lar mutations in RIF-resistant M. tuberculosis isolates may
differ in different geographic areas,4 generally the most frequent
codon involved is also 531.15,37,50
In contrast, resistance to INH was associated with a variety
of mutations. The katG gene, which encodes catalase-peroxi-
dase, was the most commonly altered gene, with the majority
of mutations occurring at codon 315 (32% of INH-resistant
strains). The absence of additional mutations within or outside
of the katG gene in fifteen of seventeen codon 315 mutated
INH-resistant strains confirms that codon 315 plays an impor-
tant role in the development of INH resistance. This is in agree-
ment with previous studies.8,38,54 The apparently conservative
substitution of serine by threonine is of a maximum benefit to
M. tuberculosis, as it reduces the activation of INH while main-
taining a substantial catalase-peroxidase activity.25,28,30,38 In-
deed, in our series, 71% and 35% of INH-resistant strains with
a mutated codon 315 showed some catalase and peroxidase ac-
tivity, respectively. The catalase-peroxidase negative strains
probably reflect the inaccuracy of the routine assays, which is
nevertheless useful in clinical laboratories.6 Like many other
authors,17,25,36,40,43,53 we found a high level of INH resistance
(4–16 g/ml) in the katG 315 mutated strains, although one
study in the literature reported contrasting figures.41 On the
other hand, it has been reported that isolates with deletions in
katG gene lost their catalase-peroxidase activities, and the MICs
for these isolates are 32 g/ml.11,30 In our study, three strains
with deletions in the katG gene were found. Two of these had
deletions affecting the catalytic domain of the protein showed
MIC of 32 g/ml and lacked catalase-peroxidase activities.
The third strain had a low-level resistance (0.25 g/ml), con-
served its catalase activity, and had a deletion of 15 bp (codons
640–644) in the C-terminal domain. Mutations affecting the
C-terminal part are either associated with low-level resistance
or appear to be without effect.12,13,36 Moreover, strains 27R,
9R, and 36R with low-level resistance and conserved catalase-
peroxidase activity had mutations in this C-terminal domain.
We failed to detect a complete katG deletion in any of these 53
resistant isolates.
The second most frequently affected codon in the katG gene
was 463 (5.6%), always in conjunction with additional muta-
tions outside this codon. Unlike mutations at codon 315, mu-
tations at codon 463 have also been detected in isoniazid-sus-
ceptible isolates,9,26,29 which suggests that it is a rather common
polymorphism, independent of INH resistance.
inhA operon consists of two genes, mabA and inhA, both of
which encode enzymes involved in mycolic acid biosynthe-
sis.2,3 Seventeen isolates in our series had mutations in the
mabA-inhA regulatory region; 14 of these strains (82%) had no
other detectable molecular alterations at katG gene. All the
COLL ET AL.110
TABLE 3. MIC TO RIFAMPIN AND MUTATIONS IN RPOB OF CLINICAL M. TUBERCULOSIS ISOLATES
rpoB gene
Strain MIC (g/ml) Codon Amino acid changes
059/R 1 512 AGC → ACC Ser → Thr
019/R 1 516 GAC → TTC Asp → Phe
005/R 4 516 GAC → TAC Asp → Tyr
063/R 4 516 GAC → GTC Asp → Val
028/R 16 526 CAC → GAC His → Asp
047/R 32 526 CAC → TAC His → Tyr
003/R 32 526 CAC → GAC His → Asp
018/R ND 526 CAC → TAC His → Tyr
016/R 8 531 TCG → TTG Ser → Leu
007/R 16 531 TCG → TGG Ser → Trp
052/R ND 531 TCG → TTG Ser → Leu
044/R 32 531 TCG → TTG Ser → Leu
039/R 32 531 TCG → TTG Ser → Leu
048/R 32 531 TCG → TTG Ser → Leu
017/R 32 531 TCG → TTG Ser → Leu
ND, not done.
strains with mutations in the mabA-inhA regulatory region had
low-level resistance (MIC 0.2–1 g/ml). The most frequent sub-
stitution involved nucleotide –15 upstream of mabA (82.3%).
Fifteen of the 17 strains (88.2%) conserved catalase activity,
and all of them had peroxidase activity. To our knowledge, no
mutations have been mapped to the MabA ORF in INH-resis-
tant organisms. In contrast, mutations have been mapped to the
mabA RBS with high frequency and also in the InhA ORF with
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TABLE 4. PHENOTYPIC AND GENOTYPIC CHARACTERISTICS OF ISONIAZID-RESISTANT STRAINS
Results of phenotypic analysis for
Activity Results of genotypic analysis for
Strain MIC (g/ml) Catalase Peroxidase katG inhA ahpC-oxyR
058/R 0.125 2 			 — — —
027/R 0.125 3 	 592 Asp → Glu — —
030/R 0.25 3 		 — — —
032/R, 041/R 0.25 3 			 — — —
039/R 0.25 1 			 — — —
040/R 0.25 1 0 94 Asp → Asn — —
046/R 0.25 0 			 463 Art → Leu –15 C → T —
054/R 0.25 2 0 640 Del — —
009/R 0.25 2 		 728 Trp → Tyr — –12G → A
067/R 0.25 0 		 — –15 C → T —
052/R 0.25 3 		 — –15 C → T —
061/R 0.25 4 			 — –15 C → T —
042/R 0.25 2 			 — –8 T → C —
034/R 0.25 3 			 — –8 T → C —
029/R 0.5 1 			 — — —
033/R 0.5 3 			 — — —
050/R 0.5 0 			 — — —
028/R 0.5 0 0 172 Ala → Thr — –6G → C
047/R 0.5 2 			 — –15 C → T —
001/R 0.5 3 			 — –15 C → T —
014/R 0.5 3 	 — –15 C → T —
013/R 0.5 4 	 — –15 C → T —
011/R 0.5 4 	 — –15 C → T –38/–39 ins
026/R 0.5 4 	 — –17 G → T —
059/R 1 3 		 — — —
036/R 1 2 	 678 Tyr → Cys –15 C → T —
003/R, 053/R 1 3 		 — –15 C → T —
060/R 1 2 		 — –15 C → T —
017/R 2 0 0 560 Gly → Ala — —
007/R 2 1 		 204 Trp → stop — —
057/R 2 0 		 189 Asp → His –15 C → T —
004/R 4 4 0 315 Ser → Thr — —
016/R 8 2 0 315 Ser → Arg — —
008/R 8 2 0 315 Ser → Asn — —
035/R 8 0 	 315 Ser → Thr — —
063/R 8 1 	 315 Ser → Thr — —
015/R 8 2 0 315 Ser → Thr — —
044/R 8 2 		 315 Ser → Thr — —
062/R 8 2 0 315 Ser → Thr — —
018/R, 045/R, 8 3 0 315 Ser → Thr — —
066/R, 023/R
048/R 8 3 	 315 Ser → Thr — —
002/R 8 4 			 315 Ser → Thr — —
019/R 8 0 0 315 Ser → Thr — –39 Del
012/R 8 3 	 315 Ser → Thr — –45/–46 ins
463 Arg → Leu — —
234 Ala → Gly — —
065/R 16 0 0 315 Ser → Thr — —
463 Arg → Leu — —
005/R 32 0 0 234 Del — —
155–158 Del — —
022/R 32 0 0 152 Del — –39 A → G
024/R 32 0 0 — — –12 G → A
lower, but significant, frequency.2,33,35 Mutations in the mabA-
inhA regulatory region result in the overexpression of the InhA
protein through transcriptional upregulation,29 and are associ-
ated with both INH and ETH resistance.19,21 The data presented
here for katG and inhA loci therefore emphasize the fact that a
mutation alone is sufficient to confer the resistance phenotype.
The promotor region oxyR-ahpC takes part in the cellular an-
swer to oxidative stress.39 In our study, genetic alterations (mu-
tations, deletions, or insertions) in the promoter region oxyR-
ahpC were identified in 13.2% of INH-resistant strains, as
described similarly in previously published reports.16,29,39,45
Conversely, taken together our data clearly demonstrate that
most strains with oxyR-ahpC region mutations have alterations
at other loci (katG or inhA), which may readily explain the INH
resistance phenotype.16,39
Our results showed, however, that 17% of the INH-resistant
isolates had no detectable alterations at the studied loci. The
fact that we sequenced the whole katG gene suggests that some
target regions are still undefined and that other molecular mech-
anisms may play some role. A similar result was found by Silva
et al. in Brazil.40 The genetic mechanisms of INH resistance
are highly complex and affect several genes that are involved
in mycolic acid biosynthesis or are overexpressed as a response
to the buildup or cellular toxicity of INH.20,30 At least 18 al-
ternative genes have been implied in the mechanism of resis-
tance to isoniazid. Among these there are the ndh (encoding
NADH dehydrogenase) fadE23, fadE24 (involved in fatty acid
-oxidation), Rv1592c, Rv1772 (of unknown function but tran-
scriptionally induced by INH), and iniBAC region (Rv0340
genes iniA, iniB, and iniC) induced by both INH and etham-
butol.
There are geographic variations in the molecular mechanism
responsible for INH resistance. S315T mutation in the katG
gene has been detected in 91.7% of INH-resistant strains in Rus-
sia,24 87% in Brazil,40 83.9% in Lithuania,1 62.2% in New
York,27 59.2% in Korea,18 34.6% in Madrid,27 32% in the pre-
sent study in Barcelona, and none of the Equatorial Guinea
strains.49 Therefore, the mapping of the frequency and types of
mutation in a country or a geographic region is not generally
applicable.
RFLP analysis indicates that transmission of INH-resistant
strains contributes to the emergence of INH-resistant tubercu-
losis in Barcelona through short transmission chains. We were
unable to identify links among many of the patients in RFLP-
defined clusters, probably due to the difficulty of reconstruct-
ing the epidemiological links in locations involving casual con-
tact outside the home.42 The absence of major outbreaks
suggests that the TB control program has been sufficiently ef-
fective. This finding is consistent with the fact that the inci-
dence of primary resistance to INH in Barcelona is low.23
With regard to the correlation between the molecular mech-
anism of INH resistance and transmission (Table 2), 10 of 15
isolates belonging to five clusters had a mutation at codon 315
of the katG gene. Substitution involving nucleotide –15 up-
stream of the mabA-inhA regulatory region was found in three
isolates belonging to one cluster. Finally, two strains belong-
ing to one cluster had no detectable alterations at the studied
loci.
In summary, the screening of codon 315 of katG gene and
the mabA-inhA upstream region should be included in a rapid
genotypic assay for direct detection of INH resistance. This tar-
get approach would cover 62% of an INH-resistant sample in
Barcelona. In contrast, if a 81-bp region of rpoB is selectively
targeted, all the RIF-resistant isolates of our series would be
rapidly detected. Such a PCR-based method would facilitate the
rapid detection and drug susceptibility testing of M. tuberculo-
sis, which is necessary for the effective control and prevention
of tuberculosis and MDR-TB. In Barcelona, this would be es-
pecially suitable to study the drug resistance among immigrants
new cases and among previously treated patients.
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